Chikungunya in Children: Unique Immune Responses and Clinical Patterns

For clinicians working in endemic regions and for parents of affected children, the synthesis sharpens our picture of who is most vulnerable and which clinical signs warrant closer attention during the acute phase and beyond.

A distinctive pediatric immune signature

The review, authored by researchers at the Department of Pediatric Respiratory Medicine at the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, walks us through the immune cascade that follows a chikungunya virus (CHIKV) infection in children. After the virus is introduced into the skin through Aedes mosquito bites and disseminates through the bloodstream, children mount a more vigorous innate response than adults do. The authors document elevated IL-18 and IFN-α2 levels alongside stronger activation of natural killer cells and macrophages, the early sentinels of antiviral defense. At the same time, antibody positivity tends to be lower and the cytotoxic T lymphocyte response is comparatively weaker. Increased IL-2 receptor alpha chain expression points to an enhanced regulatory T cell response — a mechanism that may help young patients avoid the excessive inflammation and chronic joint damage that more frequently define the adult clinical course.

Clinical presentation across pediatric age groups

This immunological profile translates into a markedly different clinical presentation. Children more often present with high fever, rash, and neurological complications, while the debilitating arthralgia and chronic musculoskeletal manifestations that define adult chikungunya are less commonly observed. The review also flags that clinical features vary across pediatric age groups, with neonates and children with compromised immune systems at particular risk of severe disease following CHIKV infection. Vertical mother-to-child transmission during intrapartum maternal viremia can produce severe symptomatic neonatal infection, and some children face long-term sequelae including epilepsy, developmental delays, and movement disorders. As we navigate these scenarios in real clinical practice, the management pathway must be calibrated to age and immune status rather than treated as a single uniform entity, and clinicians should keep neurologic and developmental surveillance on the long-horizon checklist for any infant or toddler who has cleared acute viremia.

A broader recognition of pediatric specialization

The timing of this synthesis coincides with renewed attention to the history of pediatric specialization itself. As reported by Gustave Roussy, April 1952 marked the opening of Europe's first pediatric oncology department under Dr Odile Schweisguth within the Milhit Pavilion — a milestone built on the recognition that children require dedicated care pathways distinct from adult medicine. The same principle applies today in infectious disease management: understanding the pediatric-specific immune cascade is essential for designing age-appropriate clinical management and protecting quality of life in the years following infection.